JP2015524421A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524421A5
JP2015524421A5 JP2015523548A JP2015523548A JP2015524421A5 JP 2015524421 A5 JP2015524421 A5 JP 2015524421A5 JP 2015523548 A JP2015523548 A JP 2015523548A JP 2015523548 A JP2015523548 A JP 2015523548A JP 2015524421 A5 JP2015524421 A5 JP 2015524421A5
Authority
JP
Japan
Prior art keywords
composition
dengue
use according
serotype
dengue virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015523548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065667 external-priority patent/WO2014016360A1/en
Publication of JP2015524421A publication Critical patent/JP2015524421A/ja
Publication of JP2015524421A5 publication Critical patent/JP2015524421A5/ja
Ceased legal-status Critical Current

Links

JP2015523548A 2012-07-24 2013-07-24 ワクチン組成物 Ceased JP2015524421A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305907.3 2012-07-24
EP12305907 2012-07-24
EP12305912.3 2012-07-25
EP12305912 2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en) 2012-07-24 2013-07-24 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071529A Division JP6830118B2 (ja) 2012-07-24 2019-04-03 ワクチン組成物

Publications (2)

Publication Number Publication Date
JP2015524421A JP2015524421A (ja) 2015-08-24
JP2015524421A5 true JP2015524421A5 (https=) 2016-09-08

Family

ID=48875047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015523548A Ceased JP2015524421A (ja) 2012-07-24 2013-07-24 ワクチン組成物
JP2019071529A Active JP6830118B2 (ja) 2012-07-24 2019-04-03 ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019071529A Active JP6830118B2 (ja) 2012-07-24 2019-04-03 ワクチン組成物

Country Status (11)

Country Link
US (2) US20150196631A1 (https=)
EP (2) EP2877208B1 (https=)
JP (2) JP2015524421A (https=)
KR (2) KR20150036592A (https=)
CN (1) CN104812407B (https=)
AU (1) AU2013295014B2 (https=)
MX (2) MX381497B (https=)
MY (2) MY197723A (https=)
PH (1) PH12014502840B1 (https=)
SG (2) SG10201912291YA (https=)
WO (1) WO2014016360A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
EP3316905A1 (en) * 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
KR102373570B1 (ko) * 2015-11-27 2022-03-10 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
WO2019069130A1 (en) * 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN116334070B (zh) * 2023-02-15 2026-02-06 天津大学 融合蛋白的应用和细胞融合的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422A (en) 1848-02-01 Spark-arrester
US109A (en) 1836-12-15 Erawijtg
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱1型ウイルスワクチン
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
KR101074175B1 (ko) * 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
JP5227172B2 (ja) 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Similar Documents

Publication Publication Date Title
JP2015524421A5 (https=)
Trovato et al. Viral emerging diseases: challenges in developing vaccination strategies
Yong et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus
McLean et al. The pig as an amplifying host for new and emerging zoonotic viruses
Belete A review on Promising vaccine development progress for COVID-19 disease
JP2017526689A5 (https=)
Ewer et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
JP2019151636A5 (https=)
JP2015524422A5 (https=)
Buczkowski et al. Morbillivirus vaccines: recent successes and future hopes
Angel et al. Dengue vaccines: Strongly sought but not a reality just yet
Li et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
O’Donnell et al. The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
Torres-Ruesta et al. Insights into antibody-mediated alphavirus immunity and vaccine development landscape
Medina et al. Virulence and immune evasion strategies of FMDV: implications for vaccine design
Babaeimarzangou et al. Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
Norrby Outlook for a dengue vaccine
Kumbhare et al. An updated comprehensive review of the dengue vaccine: development, mechanism, efficacy, and safety
Wang et al. Research advances in replication-deficient viral vector vaccines
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
Paton et al. Developing vaccines against foot-and-mouth disease and some other exotic viral diseases of livestock
Kim et al. Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus